European Atherosclerosis Society

High Lipoprotein(a) [Lp(a)] affects almost 20% of the world's population and has been strongly linked to atherosclerosis and aortic valve disease. Currently, there are no specific therapies to lower Lp(a), but they are coming in due time. Screening for high Lp(a), good risk evaluation, and intensive LDL-C lowering for at-risk people can save lives. Very important, like in Familial Hypercholesterolemia, family checking for high Lp(a) is essential for early prevention. https://lnkd.in/dkU-9Kqw will convene patients, specialists, scientific societies, and politicians to discuss increasing awareness and reducing the burden of disease related to Lp(a). I'm proud and honored to represent Brazil and the Global Heart Journal! FH Europe Foundation, International Atherosclerosis Society (IAS), European Atherosclerosis Society, World Heart Federation, Hospital Albert Einstein #LpaGlobalSummit

Join the European Atherosclerosis Society 4-7 May 2025 in Glasgow for #EASCongress2025, exploring the latest developments in basic, translational and clinical research into the causes of atherosclerosis and related vascular disease. Find out more on our website 👉 https://lnkd.in/erfNPEw7

At EAS, researchers and healthcare professionals worldwide unite to share knowledge, advance research, and improve the prevention and treatment of atherosclerosis and related diseases. Collaborate with us and make an impact: https://lnkd.in/e7eGpU5H

The Executive Committee of the European Atherosclerosis Society met in Copenhagen. Prior to the official proceedings, we had the opportunity to explore Danish design and admire the beauty of the city. A perfect blend of business and leisure. Børge Nordestgaard Kausik Ray MD FMedSci Meral KAYIKCIOGLU Marianne Benn Christoph Binder Tania Börjesson Karolina Andersson Carmel Hayes Jeanine Roeters van Lennep Kirsten Holven Alberto Zambon EVANGELOS LIBEROPOULOS Shoaib Afzal Ulrich Laufs

Join us tomorrow at the Royal Society of Medicine-London for an all star course on lipids

This recent study sheds light on the complex relationship between kidney dysfunction and ischemic heart disease (IHD), revealing key global trends and disparities. Despite overall declines in death rates in nearly 70% of countries, there are still significant inequalities across nations 🔎 Key insights from the study: ✅ The global age-standardized death rates (ASDR) for IHD linked to kidney dysfunction have generally declined, with a downward trend in almost all countries. ✅ Men are more affected by IHD attributed to kidney dysfunction than women, with the burden increasing as age rises. ✅ Cross-country inequalities persist, disproportionately impacting countries with lower socio-demographic indices, especially in poorer regions. 🌿 While the overall trend is positive, significant health disparities remain—particularly in low-income nations where the burden of disease continues to be disproportionate. Economic factors, such as GDP growth, have been shown to influence these inequalities, making it crucial to address these gaps through targeted interventions. 👉 Dive deeper into the findings of this important study: https://lnkd.in/dKntAbPe 📢 How can we reduce health disparities and improve outcomes in lower-income countries? Share your thoughts in the comments! European Atherosclerosis Society

🌍 Exciting news! I am honored to be attending the 1st Global Summit on Lp(a) in Brussels on March 24-25, 2025! This groundbreaking event brings together global experts to raise awareness and shape the future of Lipoprotein(a) testing and management. Thrilled to contribute to this important initiative and collaborate with colleagues from around the world. Let’s work together to make Lp(a) a priority in cardiovascular health! 💙 📍 Brussels, Belgium 📅 March 24-25, 2025 🔗 #LpaGlobalSummit #Cardiology #Lipoprotein(a) #CVHealth FH Europe Foundation | European Atherosclerosis Society | International Atherosclerosis Society (IAS) | Global Heart Hub | World Heart Federation

With the EAS Executive Committee meeting now behind us, we move forward into the next phase. Countless important topics were discussed, and change is already on the horizon.

Meet the GRIPonMASH partner: Roche Roche is focused on exploring the clinical utility of blood-based biomarkers—a crucial step toward improving early detection and patient care, especially in primary care settings, where better diagnostic tools are urgently needed. Together, we are working towards a healthier future! #MASH #MASLD #biomarkers #consortium #clinicaltrials

Only two weeks left to register at regular rates for #EASCongress2025. Don’t wait any longer - secure your spot in Glasgow! https://bit.ly/3UYJAKF #CardiovascularHealth #Cardiovascular #AtherosclerosisResearch #HeartHealthExperts